A new multicenter randomized trial study, NHALE-1, coauthored by Emory University’s Dr. Kristina Cossen and Jaeb Center for Health Research’ Roy Beck, found that use of inhaled technosphere insulin (TI) for children and adolescents with type 1 diabetes. Across 230 participants (ages 4–17), TI did not achieve noninferiority to rapid-acting analog insulin (RAA) for HbA1c over 26 weeks.
However, several meaningful findings emerged Key Results: • Safety: TI was well tolerated with no differences in pulmonary function and low severe hypoglycemia rates. • Glycemic Metrics: Time-in-range was comparable between TI and RAA. • Patient Experience: Youth using TI reported higher treatment satisfaction.
• Weight Outcomes: TI users showed less weight and BMI percentile gain than those using RAA. Although not replacing standard therapy, TI offers a safe alternative that may benefit select pediatric patients, especially those prioritizing convenience, treatment satisfaction, and weight-related outcomes.
PediatricDiabetes Type1Diabetes Endocrinology ClinicalTrials EmoryResearch ChildHealth DiabetesCare Read more: lnkd.in/gUAD4TSZ
